Document:

EX-10.18

 Exhibit 10.18 

MASTER SERVICES AGREEMENT 

This Master Services Agreement (the “Agreement”) is made as of the 14th day of August, 2015 (“Effective Date”) by and
between RegenMedTX, LLC, a Delaware limited liability company (“Sponsor”) with offices located at 3929 Westpoint Blvd., Suite G, Winston-Salem, NC 27103, and CTI Clinical Trial Services, Inc. & CTI Clinical Consulting Services, Inc.,
(“CTI”) with offices located at 10123 Alliance Road, Cincinnati, OH 45242. 
 Introduction 

Sponsor may sponsor and/or conduct one or more clinical research studies from time to time, and CTI is knowledgeable and experienced in the design, management
and conduct of such studies. Sponsor wishes to retain CTI to assist Sponsor in these studies on the terms and conditions set forth in this Agreement. 
 To
that end, Sponsor and CTI now agree as follows: 
 1. Services. From time to time, CTI will provide Sponsor certain
clinical research or design and development services pursuant to the terms of this Agreement. Prior to the commencement of such services, CTI and Sponsor shall enter into a Work Order that will describe the specific obligations transferred by
Sponsor to CTI (the “Services”) in the performance of a particular clinical research study sponsored or conducted by Sponsor (each a “Study”). Each Work Order will be a separate agreement, and each Work Order will incorporate the
terms of this Agreement by reference. A sample form of this Work Order is attached to this Agreement as Exhibit A. 
 CTI represents
to Sponsor that it is not a party to any agreement which would prevent it from fulfilling its obligations under this Agreement and, that during the term, CTI agrees it will not enter into any agreement to provide services which would in any way
prevent it from providing the Services as contemplated under this Agreement. 
 CTI will ensure that the Services are carried out by
qualified and experienced staff. CTI covenants that it will render the Services in accordance with its applicable standard operating procedures and to the highest professional standards·and will make all efforts to maintain consistently high
levels of accuracy and expertise. CTI will comply with all applicable laws, rules, regulations and guidelines relating to the conduct of clinical investigations, including, without limitation, 21 C.F.R. Parts 50, 54, 56 and 312, the International
Conference on Harmonization Guidelines for Good Clinical Practices (collectively, “Applicable Law”) and other good clinical practice requirements (collectively, “Applicable Requirements”). The parties agree to comply with the
Health Insurance Portability and Accountability Act (45 C.F.R. Parts 160, 162 and 164, as well as the regulations thereunder) and any state, municipal or local law, ordinance or regulation protecting the privacy of individual health information
(collectively “Privacy Laws and Regulations”). 

 2. Personnel. CTI shall ensure that appropriately trained and qualified
employees and contractors of CTI deliver the Services outlined in each Work Order. CTI must obtain the prior written consent of Sponsor regarding any contractor which CTI proposes to engage to deliver the Services outlined in any Work Order. CTI
also must obtain the prior written consent of Sponsor with respect to a decision by CTI to utilize any CTI employee that CTI proposes to have a substantive role in the delivery of the Services with respect to any Work Order that is not so engaged as
of the Effective Date. However, such prior written consent shall not be required with respect to those employees whose involvement in the Study is limited to only non-substantive activities (e.g., monitors,
etc.). 
 If CTI contracts with investigators or investigative sites (collectively, “Investigators”), any such contract shall be
on a form mutually acceptable to CTI and Sponsor. If an Investigator requests any material changes to such form, CTI shall submit the proposed change to Sponsor, and Sponsor shall promptly review, comment on and/or approve such proposed changes. The
parties acknowledge and agree that Investigators shall not be considered the employees, agents, or subcontractors of CTI or Sponsor, and that Investigators shall exercise their own independent medical judgment with respect to the applicable Study.
CTI’s responsibilities with respect to Investigators shall be limited to those responsibilities specifically set forth in this Agreement and any applicable Work Order. 

If CTI will be paying Investigators on behalf of Sponsor, the parties will agree to a schedule of amounts to be paid to Investigators. Sponsor
acknowledges and agrees CTI will only pay Investigators from advances or pre-payments received from Sponsor for Investigators’ services, and that CTI will not make payments to Investigators prior to
receipt of sufficient funds from Sponsor. Sponsor acknowledges and agrees that CTI will not be responsible for delays in a Study to the extent that such delays are caused by Sponsor’s failure to make adequate
pre-payment for Investigators’ services. Sponsor further acknowledges and agrees that payments for Investigator’s services are pass -through payments to third parties and are separate from
payments for CTI Services. Sponsor agrees that it will not withhold Investigator payments except to the extent that it has reasonable questions about the services performed by a particular Investigator. CTI shall have Investigators complete and
return to Sponsor such financial disclosure forms as may be required to comply with Applicable Regulations pertaining to financial disclosures of clinical investigators. 

The parties agree that any payments to Investigators are not intended to encourage, and are not being given in exchange for any explicit or
implicit agreement to: 
 (i) order, purchase, prescribe or recommend any Sponsor product; or (ii) influence or provide favorable formulary status for
any Sponsor product. Payments have not been determined in a manner that would take into account the volume or value of referrals or business, if any, generated between Sponsor and any investigator,
sub-investigator or their practice. 

  
 2 

 By entering into this Agreement, each party attests that it understands what is required of it for the Study
under Applicable Law and Applicable Requirements, and commits to complying with such law and requirements. CTI hereby certifies to Sponsor that it is not, has not been, or has not used, nor will it use the services of any person, debarred under 21
U.S.C. 335a, as amended, or disqualified by any regulatory authority, or otherwise found by any regulatory authority to have violated any Applicable Law or Applicable Requirements concerning the conduct of clinical investigations or excluded from
participation in any state or federal healthcare program (collectively, “Debarred” or “Debarment”) in any capacity in connection with any of the services or work provided hereunder. In the event that during the term of this
Agreement, CTI or any of its Investigators or any of their employees or agents (i) becomes Debarred or (ii) receives notice of an action or threat of an action with respect to its Debarment, CTI shall notify Sponsor immediately. 

3. Transfer of Obligations. The specific obligations transferred by Sponsor to CTI in any particular Study will be detailed in
the relevant Work Order. Sponsor will retain those responsibilities not specifically listed in that Work Order. Sponsor shall at all times be the “Sponsor” of each Study pursuant to the terms of the U.S. Food, Drug and Cosmetic Act, as
from time to time amended (the “Act”). Sponsor will maintain all direct communication, whether oral, electronic or hard copy, with the U.S. Food and Drug Administration (the “FDA”) at all times with respect to the Study, and CTI
will only engage in limited preliminary communications with the FDA regarding the Study and shall give prompt notice of such communications to Sponsor. Sponsor will cooperate with CTI in taking any action that CTI reasonably believes is necessary to
comply with the regulatory obligations that have been transferred to CTI. 
 Each party acknowledges that the other party may respond
independently to any regulatory correspondence or inquiry in which such party or its affiliates is named and which does not relate to the Services provided under this Agreement. Each party however, shall: (a) notify the other party promptly of
any FDA or other U.S. or non-U.S. governmental or regulatory inspection or inquiry relating to the Services provided by CTI under this Agreement including, but not limited to, inspections of investigational
sites; (b) forward to the other party copies (within five (5) business days) of any correspondence from any regulatory or governmental agency relating to a Study, including, but not limited to, Form
FD-483 notices, and FDA refusal to file, rejection or warning letters, even if they do not specifically mention the other party; (c) give the other party the opportunity to review and comment upon any
response to a regulatory authority relative to the Services or a Study under this agreement before such response is submitted, such review and comment to be conducted promptly and without delay; and (d) obtain the written consent of the other party,
which will not unreasonably be withheld, before referring to the other party or any of its affiliates in any regulatory correspondence relative to the Services or a Study under this Agreement. Where reasonably practicable, each party will be given
the opportunity to have a representative present during a FDA or regulatory inspection. Each party however, acknowledges that it may not direct the manner in which the other party fulfills its obligations to permit inspection by 

  
 3 

 governmental entities. Notwithstanding the foregoing, CTI will promptly notify Sponsor of any FDA or other
U.S. or non-U.S. governmental or regulatory inspection or inquiry with respect to CTI not relating to the Services or the Study but which is reasonably likely to have an impact on CTI’s perfonnance of the
Services and/or its other obligations under this Agreement and, to the extent legally permissible, discuss with Sponsor such potential impact. 

Each party agrees that, during an inspection by the FDA or other regulatory authority concerning any Study for which CTI is providing the
Services, it will not disclose information and materials that are not required to be disclosed to such authority, without the prior written consent of the other party, which shall not unreasonably be withheld. Such information and materials
includes, but are not limited to (i) financial data and pricing data (including, but not limited to, the Budget (as defined below)); (ii) sales data (other than shipment data); and (iii) personnel data (other than data as to qualification
of technical and professional persons performing functions subject to regulatory requirements). 
 During the tenn of this Agreement, CTI
will permit Sponsor’s representatives (unless such representatives are competitors of CTI) to examine and review, without any additional cost to Sponsor, the work performed hereunder and any facilities at which the work is conducted, upon
reasonable advance notice and at mutually agreeable times during regular business hours to detennine that the Services are being perfonned in accordance with this Agreement and the Work Orders. In the event of a more formal audit, unless the costs
of governmental or Sponsor audits are specifically included in the Budget, or a governmental “for cause” audit is conducted as a result of CTI activities, Sponsor shall reimburse CTI for its time and expenses, including reasonable attorney
fees, associated with such audits, including the costs of responding to the findings of any such audit. 
 4. Scope of Work and
Payment. The Work Order for each Study will include a scope of work statement that details CTI’s Services for that Study. The Work Order will also include a budget and payment schedule for CTI’s Services for each Study, and Sponsor
will pay CTI for the Services accordingly (“Budget”). The aggregate fees and expenses set forth in that schedule will not change or be modified unless authorized by both parties in writing. CTI will invoice Sponsor in accordance with the
relevant Work Order. Each invoice will describe the Services performed, and any expenses billed will be supported by appropriate documentation. Sponsor will pay all uncontested amounts reflected on each invoice within thirty (30) days of the
date thereof. If all or any portion of an invoice is contested, Sponsor will provide written notice and a summary of the contested items to CTI within ten (10) days of Sponsor’s receipt of invoice. The parties shall work in good faith
toward resolution of such items. 

  
 4 

 If Sponsor requests CTI to perform services beyond those set out in the Work Order, CTI
shall proceed as follows: consistent with the desire of both parties not to disrupt the ongoing progress of any Study, CTI shall (i) submit a proposed budget and payment schedule for such out-of-scope work and obtain Sponsor’s written approval of that schedule before commencing that work, or (ii) obtain written authorization from Sponsor to proceed with such work prior to a final
agreement on the proposed schedule. In either case, both parties will make good faith efforts to negotiate and agree upon a revised schedule as soon as possible and practicable. 

5. Term and Termination. This Agreement and any Work Order will begin as of its stated Effective Date and will continue unless
terminated under this Section 5. This Agreement or any Work Order may be terminated for any reason by any party upon ninety (90) days prior written notice to the other party. Further, this Agreement or any relevant Work Order may be
terminated immediately by written notice from Sponsor, in the following circumstances: 
  

	 	(1)	 The FDA withdraws authorization and approval to conduct a Study; or 

 

	 	(2)	 Sponsor reasonably determines that for medical, clinical or patient safety reasons, a Study should terminate
immediately. 

 In addition, either party may terminate this Agreement or any Work Order for material breach upon thirty
(30) days written notice specifying the nature of the breach, if such breach has not been substantially cured within the thirty (30) day period. 

For any termination of this Agreement or any Work Order, both parties recognize that such an event will require discussion, cooperation and
coordination between them to ensure patient safety, compliance with all applicable regulations and continuity of treatment (if appropriate). To that end, upon any termination of this Agreement or any Work Order, CTI will cooperate with Sponsor to
provide for an orderly cessation of CTI Services. Additionally, unless otherwise stipulated by Sponsor, CTI will perform such Services as are reasonably necessary for an orderly termination and shall transfer to Sponsor all Study data, reports, and
all related Study documents prepared but not yet submitted to Sponsor after receiving full payment from Sponsor for all services and work related to such Study data, reports and Study documents. Similarly, upon any termination of this Agreement or
any Work Order, Sponsor shall promptly pay CTI for Services performed under this Agreement or such Work Order prior to the effective date of termination or in connection with the process of an orderly termination; provided, however, that the total
of such payments shall not exceed the total amount remaining under the Budget unless agreed to by Sponsor and CTI in writing. Sponsor’s final payment to CTI will include reimbursement to CTI for all
non-cancelable obligations and all pass-through expenses incurred prior to the effective date of termination or in connection with the process of an orderly termination. In the orderly cessation of activities,
CTI will use its best efforts, consistent with good clinical practice, to minimize costs to be incurred by Sponsor for the Services. 

  
 5 

 6. Confidentiality. For this Agreement and its Work Orders, all materials,
documents and information concerning a Study, including, without limitation, the protocol, case report forms, clinical data and other proprietary data provided to or developed by CTI for use in a Study, shall be considered “Confidential
Information.” All Confidential Infonnation, except CTI Intellectual Property as defined in Section 7.D. below (“Records”), will be the exclusive property of Sponsor. CTI will maintain Confidential Information in confidence and
shall not disclose it unless that disclosure is required for CTI’s performance of its obligations under this Agreement or a Work Order. Unless otherwise agreed in a Work Order, CTI’s confidentiality obligations shall survive for seven
(7) years after the expiration or termination of the relevant Work Order. CTI is responsible for ensuring that all of its employees and contractors understand and maintain the confidentiality of such Confidential Information under this
Agreement or its Work Orders. 
 Under this Agreement and its Work Orders, Confidential Information shall not include: (a) information
which is known to CTI prior to disclosure by Sponsor; (b) information which is or becomes public through no improper act of CTI; (c) information which becomes available to CTI from a source other than Sponsor; or (d) information
developed by or for CTI independent of the disclosure of Confidential Information by Sponsor. 
 The parties may disclose Confidential
Infonnation to the extent such disclosure is required to comply with applicable governmental regulations or to the extent ordered by a court exercising its right of authority over the disclosing party (subject to entry of an appropriate protective
order), provided that if a party is required by such law, regulation or order to make any such disclosure of Confidential Infonnation, such party shall give reasonable notice to the other party of such disclosure requirement and will use its
reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed. 
 CTI shall maintain all
Records in a safe and secure manner and in compliance with all Applicable Laws and Applicable Requirements. CTI shall store all Records in compliance with the appropriate record retention regulations. Thereafter, prior to disposal of any Records,
CTI shall give Sponsor not less than sixty (60) days written notice, and, if Sponsor so requests prior to such disposal, CTI shall transfer such Records to Sponsor at Sponsor’s cost and expense. CTI shall make any and all Records available
for inspection or duplication by Sponsor’s authorized representatives during normal business hours at mutually agreed upon times. At any time and at Sponsor’s cost and expense, Sponsor may request that CTI (i) deliver any or all
Records to Sponsor or to a location specified by Sponsor, or (ii) dispose of Records as directed by Sponsor, unless such Records are required by Applicable Laws and Applicable Requirements to be stored or maintained. CTI shall be entitled to
retain one (1) copy of any Confidential Information necessary for determining its ongoing obligations pursuant to this Agreement. 

  
 6 

 7. Intellectual Property. 

 

	A.	 Ownership. All materials, documents and information obtained by, developed by or provided to CTI by or
on behalf of Sponsor as part of CTI’s Services under this Agreement or any Work Order will be the exclusive property of Sponsor. 

  

	B.	 Inventions. CTI will disclose to Sponsor any and all inventions or discoveries that incorporate
Confidential Information and that are made by CTI as part of its Services under this Agreement or any Work Order (“Intellectual Property”). Further, CTI will assign all rights it may have in any such Intellectual Property to Sponsor.

  

	C.	 Assistance. CTI will cooperate with Sponsor in executing any and all applications, assignments or other
instruments reasonably necessary to apply for and obtain a patent in the United States or any foreign country, or to otherwise protect Sponsor’s interest in such Intellectual Property. Sponsor shall compensate CTI for its time and reasonable
expenses required by this assistance. 

  

	D.	 Notwithstanding subsection A, B, and C above, all computer programs, software, applications, databases,
proposals and other documentation generally used or developed by CTI, and any improvement, alteration or enhancement to these (unless specifically requested and paid for by Sponsor as part of CTI’s Services under this Agreement and any
Work Order), are the exclusive and confidential property of CTI or the third parties from whom CTI has secured the right of use (“CTI Intellectual Property”). 

8. Indemnification. 

CTI will hold harmless and indemnify Sponsor, its employees, agents, representatives and assigns from and against all claims, costs,
complaints, or lawsuits that arise as a result of the negligence or malfeasance of CTI or its employees, agents, representatives, and assigns in its performance under this Agreement or any Work Order. This CTI indemnification does not apply to any
loss, damage, cost or expense to the extent such loss, damage, cost or expense is caused by or attributable to the negligence or malfeasance of Sponsor or any of its employees, agents, representatives or assigns. 

Sponsor will hold harmless and indemnify CTI, its employees, agents, representatives and assigns from and against all claims, costs,
complaints, or lawsuits that arise as a result of (i) the negligence or malfeasance of Sponsor or its employees, agents, representatives and assigns, or (ii) personal injury or death alleged to have been caused by or attributed to any
Study substance provided by Sponsor and dispensed or administered in the Study pursuant to the provisions of the Study Protocol. CTI will promptly notify Sponsor of any such claim, complaint or lawsuit. Sponsor has the right, in its sole discretion,
to defend, and/or settle any such claim, complaint, or lawsuit at its own expense and by its own counsel. CTI will cooperate fully in the investigation and defense of any such claim, complaint or lawsuit. This Sponsor indemnification does not apply
to any loss, damage, cost or expense to the extent such loss, damage, cost or expense is caused by or attributable to the negligence or malfeasance of CTI or any of its employees, agents, representatives or assigns. 

  
 7 

 9. Independent Contractor Relationship. The parties to this Agreement and its
Work Orders are independent contractors. Neither party can offer or agree to incur or assume any obligations or commitments in the name of or on behalf of the other, except as specifically stated in this Agreement or in a Work Order. 

10. Miscellaneous. 
  

	A.	 Delegation and Subcontracts. CTI may delegate part of its Services under a Work Order to its affiliated
companies or other subcontractors as it may require, and with written notice to Sponsor of that delegation. However, CTI remains principally responsible to Sponsor for the performance of all its Services and obligations under this Agreement, whether
delegated, subcontracted or otherwise. 

  

	B.	 Non-Solicitation. During the term of this Master Agreement and for a period of twelve (12) months
thereafter, neither Sponsor nor CTI shall recruit or otherwise induce any employee to terminate his/her.employment or violate any agreement with, or duty to, Sponsor or CTI. 

 

	C.	 Force Majeure. Either party shall be excused from performing its obligations under this Agreement or any
Work Order if their performance is delayed or prevented by a cause beyond that party’s control, including, but not limited to, acts of God, fire, explosion, weather, disease, war, insurrection, civil strife, riots, government action, or power
failure. Performance will be excused only to the extent of and during the reasonable continuance of such disability. Any deadline or time for performance specified in a Work Order which falls due during or subsequent to the occurrence of any
force majeure under this section will be extended for a period of time equal to the period of such disability. CTI will promptly notify Sponsor if, by reason of any force majeure, CTI is unable to meet any deadline or time for
performance specified in a Work Order. 

  

	D.	 Binding Agreement. This Agreement is binding on and inures to the benefit of its parties and their
respective legal representatives, successors and assigns. However, neither party can transfer or assign this Agreement without the prior written consent of the other party. 

 

	E.	 Amendments. This Agreement may be modified or amended only by a writing executed by the parties hereof.

  

	F.	 Notices. All notices shall be in writing and shall be personally delivered or sent by certified mail, return
receipt requested to the parties at the addresses each party will furnish to the other. 

  
 8 

	G.	 Waiver. The waiver or breach of any term or condition of this Agreement does not constitute a waiver of
any other of its terms or conditions or any subsequent breach of the same term or condition. 

  

	H.	 Entire Agreement. This Agreement and its Work Orders are the entire agreement between its parties as to
its subject matter. There are no representations, warranties, covenants or undertakings as to that subject roarer other than those expressly set forth in this Agreement and its Work Orders. This 11greement and Work Orders supersede all prior
agreements between the parties as to its subject matter. 

  

	I.	 Severability. The invalidity or unenforceability of any Agreement or Work Order provision shall in no
way affect the validity or enforceability of any other provision. 

  

	J.	 Governing Law. The laws of the State of Delaware (without regard to any provision or rule applying the
law of another state or jurisdiction) shall govern this Agreement and its Work Orders. 

  

	K.	 Counterparts. This Agreement and its Work Orders may be executed in two (2) counterparts and by
facsimile or electronic means, each of which shall be considered an original, but are one and the same document. 

[Signature page follows] 

  
 9 

 As witness to this Agreement, the authorized representatives of its parties have signed this Agreement below
as of its Effective Date. 
  

									
	CTI Clinical Trial Services, Inc.	 		 	
					
	By:	 	/s/ Timothy J. Schroeder	 		 		 	Date: 14 August 2015
	Name:	 	Timothy J. Schroeder	 		 		 	
	Title:	 	CEO	 		 		 	
				
	RegenMedTX, LLC	 		 		 	
					
	By:	 	/s/ Timothy A. Bertram	 		 		 	
	Name:	 	Timothy A. Bertram	 		 		 	
	Title:	 	Chief Executive Officer and Managing Director	 		 		 	Date: 17 August 2015

  

  
 [Signature Page to Master
Services Agreement]EX-10.19

 Exhibit 10.19 

This Laboratory Service Agreement (”Agreement”) is made effective on 26 August 2016 by and between 

 

	(1)	 COVANCE CENTRAL LABORATORY SERVICES LP an Indiana limited partnership, with its principal place
of business at 8211 SciCor Drive, Indianapolis, Indiana 46214, USA; and COVANCE CENTRAL LABORATORY SERVICES SÀRL, with its principal place of business at Rue Moise-Marchines 7, 1217 Meyrin, Geneva Switzerland
(collectively “Covance”); and 

  

	(2)	 RegenMed (Cayman) Ltd., 10 Market Street, No. 774 Camana Bay, Grand Cayman KY1-9006, Cayman Islands (“Sponsor”). 

 (each a
“Party” and collectively the “Parties”). 
 WHEREAS 

 

	(A)	 Covance is engaged in the business of providing laboratory testing, data management, protocol management and
information management services for pharmaceutical clinical trials. 

  

	(B)	 Sponsor desires for Covance to perform such services for one or more clinical trials, all in accordance with
and subject to the terms and conditions of this Agreement. 

 IT IS AGREED 

 

	1.	 DEFINITIONS 

  

	 	1.1	 In this Agreement, the following words and expressions shall have the following meanings:

 “Affiliate” means any entity controlling, controlled by, or in common control with a Party. For
the purposes of this definition, “Control” shall mean ownership or control, directly or indirectly of more than fifty percent (50%) of the common voting stock or ordinary shares in the entity or the right to appoint fifty percent
(50%) or more of the directors of that entity. With respect to Covance, the term Affiliate shall include Laboratory Corporation of America Holdings and any business entity that is controlled by or is under common control with Laboratory Corporation
of America Holdings. 
 “Anti-Corruption Laws” means any anti-bribery and anti-corruption laws, rules, regulations
applicable to either Party (each as amended from time to time) including the United States Anti-Kickback Law, United States Foreign Corrupt Practices Act, the UK Bribery Act 2010 and the OECD Convention Against the Bribery of Foreign Government
Officials in International Business Transactions, together with any applicable implementing legislation including any applicable local law addressing bribery or corruption. 

“Applicable Law” means applicable federal, state and local laws, rules, regulations, including the regulations of the FDA and
Data Protection Laws. 
 “Background IP” means all pre-existing intellectual
property belonging to or licensed to a Party or other intellectual property created outside the scope of the Services. 

  
 1 of 21 

 “Claim” means any third party claims, demands, assessments, actions, suits,
proceedings, or settlements. 
 “Confidential Information” means any and all
non-public information or materials and derivatives thereof, in any and all forms, howsoever disclosed or obtained, including business plans, financial information, client lists, and requirements, techniques,
designs, methods, processes and procedures, which: (i) is identified by a suitable legend or other marking as being confidential (or similar designation) in a prominent position or (ii) is described as being confidential at the time of
disclosure or (iii) the disclosing Party regards or should reasonably be expected to regard as proprietary and confidential given the nature of the information and the circumstances of disclosure. Confidential Information shall not include
information (a) that is or becomes publicly disclosed except to the extent such disclosure results from a violation hereof or any improper action or inaction by Recipient or any agent or representative of Recipient; (b) that was in
Recipient’s possession prior to Recipient’s receipt of such material from Disclosing Party, as demonstrated by documentary evidence that itself was in Recipient’s possession at the time of Disclosing Party’s disclosure of such
Confidential Information to Recipient; (c) that is lawfully acquired by Recipient from a third party not obligated to keep such information confidential; or (d) that is developed by the Recipient without the use of or reliance on the
Disclosing Party’s Confidential Information, as demonstrated by Recipient’s written records. Information will not be deemed to be within the foregoing exceptions merely because such information is embraced by more general information that
is within the foregoing exceptions. In addition, any combination of features will not be deemed to be within the foregoing exceptions merely because individual features are within the exceptions, but only if the combination itself and its principle
of operation are within the exceptions. 
 “Covance Property” means inventions, proprietary processes, software (including
codes) data, technology, know-how and other intellectual property that have been independently developed or discovered by Covance or its Affiliates without the use of Sponsor’s Confidential Information,
including those that relate to the proprietary innovative testing procedures, laboratory testing data collection or data management procedures, procedural manuals, delta flags, nucleic acid based vectors, analytical procedures and approaches that
are not specific for use with the Sponsor’s Background IP even if such are developed in the performance of the Services or are captured in documents pertaining to the Services (i.e. laboratory notebooks), techniques, skills, models, non-product specific components of questionnaires, management tools and any other materials, employed, developed or acquired by Covance or its Affiliates. 

“Data Protection Laws” mean all applicable privacy, data protection or similar laws and regulations anywhere in the World, as
the same may be amended from time to time, including to the extent applicable to the respective Services, the Data Protection Directive (95/46/EC), the Personal Data Protection Act 2012 of Singapore and any applicable implementing legislation or any
amendment thereto. 

  
 2 of 21 

 “Deliverables” means as applicable to the Services, Results, or any other
deliverable specified in this Agreement. 
 “Disclosing Party” means the Party disclosing or making available its
Confidential Information to the other Party. 
 “FDA” means the United States Food and Drug Administration or any other
government body or agency that succeeds it. 
 “Force Majeure Event” means circumstances or causes beyond the reasonable
control of a Party, including war, threat of war or warlike conditions, blockade, embargo, fire, explosion, lightning, storm, drought, flood, earthquake or other natural disaster, pandemic or epidemic, power failure, acts of terrorism, riot, civil
unrest, insurrection, acts of government or other international bodies, political subdivision and any other events which by their nature could not have been foreseen by the Parties, or, if it could have been foreseen were unavoidable by a reasonable
prudent business. 
 “HBS Donor” means an individual, living or deceased, from whom the HBS was obtained. 

“Human Biological Samples” or “HBS” means any human biological material, including, without limitation, human
bodily parts and organs in whole or sub-samples, any tissue, skin, bone, muscle, connective tissue, blood, cerebrospinal fluid, cells, gametes, or sub-cellular
structures such as DNA, or any derivative or product of such human biological materials including stem cells, cell lines, bodily fluids, blood derivatives and urine. 

“IEC/IRB” means an independent ethics committee or institutional review board. 

“Informed Consent” means an IEC/IRB approved informed consent form signed by the HBS Donor authorizing the Use of their HBS.

 “Invention” means any patentable invention or other registerable intellectual property rights discovered, conceived of or
made by Covance or its Affiliates specifically as result of the Services for the Sponsor and relating to the Test Materials. Covance Property is not included in Inventions. 

“Loss” means any loss, cost, damage or expense (including reasonable legal expenses). 

“Project” means a Study, project or assignment between Covance and Sponsor. 

“Protocol” means the document which specifies the laboratory testing procedures as written by Sponsor as applicable for the
performance of a Study and is provided to Covance. 
 “Recipient” means the Party receiving or having access to the
Confidential Information from the other Party. 

  
 3 of 21 

 “Regulatory Authority” means any national or state (in the case of the US),
or local agency, authority, department, inspectorate, minister, ministry official, parliament or public or statutory person (whether autonomous or not) of any government of any country having jurisdiction over either any of the activities
contemplated by this Agreement or the Parties. 
 “Regulatory Requirements” means all laws, statutes, acts, rules,
regulations, guidelines, codes, orders, directives or other legally binding requirements of any Regulatory Authority and industry standards or codes of conduct applicable to the Services. 

“Results” mean materials, data, Inventions, documents and information produced, conceived or developed by Covance specifically
as a result of the Services and related to the Test Materials. Covance Property is not included in Results. 
 “Services”
means the services provided by Covance to the Sponsor as more particularly described in this Agreement and the SOW. 
 “SOW”
means the scope of work mutually agreed to in writing by the Parties, which will be attached hereto as an exhibit and will be governed by and is hereby made a part of this Agreement. 

“Sponsor Information” means Test Materials, data, specification, or other materials or information supplied by the Sponsor to
Covance in connection with the Services. 
 “Study” means a clinical trial or scientific evaluation of the Test Materials on
the terms and conditions of the Protocol. 
 “Subcontractor” means a third party approved, reviewed and contracted by
Covance for Services within the scope of this Agreement. 
 “System Data” means control data from laboratory tests or
transactional, volume and performance data related to the Services, which does not contain any personally identifiable information or Sponsor Confidential Information. 

“Test Materials” means compounds, materials or other substances as described in the Protocol to be tested or used in the
performance of the Services and provided to Covance by the Sponsor. 
 “Use” (in the context of Section 13) means
collection, storage, transfer (including import and export), use and return or disposal of HBS including by commercial organizations. 

“Vendor” means third-party service providers other than a Subcontractor for which Covance may hold the contract with such
service provider at Sponsor’s written request for the convenience or benefit of the Sponsor in connection with Services under this Agreement. 

  
 4 of 21 

	 	1.2	 In this Agreement, unless the context otherwise requires, references to: 

 

	 	(a)	 Schedule and Section headings are inserted for convenience only and do not affect the construction or
interpretation of this Agreement; 

  

	 	(b)	 a particular law or statutory provision is a reference to it as it is in force for the time being taking
account of any amendment, extension, or re-enactment and includes any subordinate legislation for the time being in force made under it; 

 

	 	(c)	 writing or written includes faxes and e-mail;

  

	 	(d)	 a person includes a corporate or unincorporated body; 

 

	 	(e)	 any gender includes all genders; 

 

	 	(f)	 including, include, in particular or any similar expression shall be construed as
illustrative and shall not limit the sense of the words preceding those terms; 

  

	 	(g)	 words in the singular include the plural and vice versa. 

 

	 	1.3	 If this Agreement is translated, the English language text shall prevail. 

 

	2.	 SERVICES 

  

	 	2.1	 Covance through itself and/or its Affiliates hereby agrees to perform Services for Sponsor’s
protocol RMCL-CL002, “A Phase 2, Prospective, Randomized, Double Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Study of Autologous Neo-Kidney Augment (NKA) in Subjects with Type 2
Diabetes and Chronic Kidney Disease” as amended from time to time, a copy of which is attached hereto as Exhibit A. Such Services shall be performed pursuant to the terms and conditions contained herein. 

 

	 	2.2	 Any changes or modifications to the Protocol and/or Services provided by Covance, or any Sponsor request
for additional Services may commence upon Covance’s receipt of Sponsors written approval of the revised SOW. Upon Sponsor’s SOW signature, Covance shall provide such Services to the Sponsor and the Sponsor shall pay for costs associated
with such Services at its current standard rates. 

  

	 	2.3	 Should a kit be lost through no fault of Covance, or should a kit expire at the investigator site,
Covance will supply replacement kits for those that are lost, expired, or otherwise rendered unusable, at an amount equal to the price listed in the Budget per kit for the same kit/visit that is being replaced. 

 

	 	2.4	 After performing Services, Covance will store the remaining Study specimens for the length of time and
under storage conditions as described in the applicable SOW. The remaining specimens may subsequently be shipped to Sponsor or another party as specified in the SOW or if not specified in the SOW, held as otherwise instructed by the Sponsor. In no
event shall Covance’s liability for any breach or default with regard to storage of an archival specimen exceed the fee it has been paid for storage of that specimen for the previous twelve (12) months. 

  
 5 of 21 

	3.	 TERM AND TERMINATION 

 

	 	3.1	 The term of this Agreement shall be for forty two (42) months commencing on
the date hereof or the conclusion of the study, whichever is earlier, and shall renew automatically for successive one (1) year periods unless a Party provides the other Party with written notice of its intention to not renew and extend this
Agreement at least sixty (60) days prior to the commencement of any such renewal term. 

  

	 	3.2	 Either Party may terminate this Agreement with immediate effect by notice in writing in the event that:

  

	 	(a)	 the other Party commits a material breach of any term of this Agreement which breach is irremediable or (if
such breach is remediable) fails to remedy that breach within a period of thirty (30) days after being notified in writing to do so; or 

  

	 	(b)	 the other Party repeatedly breaches any of the terms of this Agreement in such a manner as to reasonably
justify the opinion that its conduct is inconsistent with it having the intention or ability to give effect to the terms of this Agreement; or 

  

	 	(c)	 anyone commences an involuntary case against such other Party under title 11 of the United States Code or the
corresponding provisions of any successor laws and either the case is not dismissed by midnight at the end of the sixtieth (60th) day after commencement; 

 

	 	(d)	 a court of competent jurisdiction appoints a custodian (as that term is defined in title 11 of the United
States Code or the corresponding provisions of any successor laws) for such other Party or all or substantially all of its assets, or such other Party makes an assignment of all or substantially all of its assets to a custodian;

  

	 	(e)	 the other Party fails generally to pay its debts as they become due (unless those debts are subject to a
good-faith dispute as to liability or amount) or acknowledges in writing that it is unable to do so; or 

  

	 	(f)	 any event occurs, or proceeding is initiated, in any jurisdiction to which it is subject that has an effect
equivalent or substantially similar to any of the events mentioned above. 

  

	 	3.3	 Sponsor may terminate this Agreement for any reason upon ninety (90) days prior written notice to
Covance. 

  

	 	3.4	 In the event of such termination, Covance shall be entitled to full payment for work performed on the
Study through the date work on such Study is concluded, including, without limitation, all fees and other out-of-pocket expenses incurred by Covance for such Study.

  

	 	3.5	 The termination of this Agreement shall not relieve either Party of its obligations to the other with
respect to: (a) maintaining the confidentiality of Confidential Information; (b) obtaining consents for the use of names; (c) ownership of and assignment of inventions; (d) indemnification; (d) limitation

  
 6 of 21 

	 	
of liability; (e) compensation for Services performed; (f) publications; and (g) retention of records. The provisions of this Section together with any other section which is
necessary for the interpretation or enforcement of this Agreement shall survive the expiry or termination of this Agreement howsoever arising. 

  

	4.	 REGULATORY COMPLIANCE 

 

	 	4.1	 Covance will perform its Services in accordance with good laboratory practices and the applicable terms
of this Agreement. All of Covance’s tests, assays and other activities undertaken under this Agreement shall comply in all material respects with College of American Pathologists (CAP) rules. Covance represents that it has and shall
maintain Clinical Laboratory Improvement Act (CLIA) certification. This Agreement shall contain all the conditions under which Covance will provide clinical laboratory Services. Covance makes no express or implied commitments or warranties
concerning the performance of the Study except as set forth in this Agreement. 

  

	 	4.2	 In the event that compliance with any regulatory requirements necessitates a change in this Agreement,
Covance will submit to Sponsor a revised technical and cost proposal for Sponsor’s acceptance prior to performing Services. 

  

	 	4.3	 In the event of a conflict in government regulations, the Parties will discuss and designate which
regulations shall be followed by Covance in its performance of the Services. 

  

	5.	 FEES, BILLING AND TAXES 

 

	 	5.1	 Fees for the Project are set forth in the attached Budget. Sponsor acknowledges that SOW finalization,
changes and/or modifications to the Project may result in a revised budget, which must be mutually agreed upon and the Agreement amended accordingly. The Budget contains all of the applicable discounts for Services that will be provided for that
Project. 

  

	 	5.2	 Upon execution, Covance will assess a fee equal to twenty percent (20%) of the value of the contract
Budget (“Project Initiation Fee”). The Project Initiation Fee covers those value-added services rendered but unbilled, including developing the Scope of Work, quality control and loading of project databases, project management and
shipping of kits. Sponsor will pay the Project Initiation Fee within thirty (30) days after receipt of invoice. 

  

	 	5.3	 Each month, Covance will invoice Sponsor for all fees due and documented expenses incurred while
providing Services during the previous month documentation for all expenses included on such invoice. Payment is due thirty (30) days from the date of the invoice. 

 

	 	5.4	 The Project Initiation Fee will be retained until the first invoice has been paid. Covance will issue a
credit on each month’s invoices equal to one-sixth (1/6) of the Project Initiation Fee. Should the Study be terminated before the Project Initiation Fee is exhausted and assuming all prior invoices have
been paid, Covance will apply Project Initiation Fee funds to the final invoice and refund any remaining Project Initiation Fee funds to Sponsor within thirty (30) days of termination. 

  
 7 of 21 

	 	5.5	 For budgeting purposes, Covance creates the Budget using local unit pricing. The local unit pricing is
then converted to the billing currency, as requested by Sponsor, using the Reuters exchange rate for the month the Budget is first created. Unless specified otherwise, this exchange rate remains unchanged during the course of the Study to simplify
budget comparisons and enable Sponsor to track changes to the Study unrelated to changes in currency exchange rates. 

  

	 	5.6	 For invoicing purposes, expenses are billed based on the contracted local unit prices. Each month, at
the time of invoice creation, the local unit prices are converted to the billing currency using the Reuters exchange rate for the month in which the expenses were incurred. 

 

	 	5.7	 Covance will hold prices unchanged for twelve (12) months from Project start up. Thereafter, a
Project is subject to a fee increase every twelve (12) months from Project start-up. Any such increase shall not exceed the annual inflation rate during the previous twelve (12) month period, as
measured by the increase in the U.S. Consumer Price Index. Fee increases apply only to Services not yet performed and invoiced on the Study. 

  

	 	5.8	 Should the Sponsor disagree with the accuracy of an invoice, the Sponsor shall notify Covance of such
inaccuracy within thirty (30) working days of receipt of the invoice. The Sponsor agrees to pay the amounts for any items not in dispute. The Sponsor agrees not to unreasonably withhold payment. 

 

	 	5.9	 If Sponsor requests a material change to the Project at any time which would affect the Services,
Covance will revise fees to reflect the change in the SOW and Budget. 

  

	 	5.10	 Upon written notification by Sponsor that the Study has been concluded or upon completion of all
Services required by Covance under this Agreement, Covance will issue a final invoice for Services rendered to identify amounts due to Covance or refund due to Sponsor. 

 

	 	5.11	 Fees payable under this Agreement shall not include local, state, federal or foreign sales or use taxes,
excise taxes, goods and services tax, value added tax or consumption taxes, as applicable. Any applicable taxes will be billed to and paid by Sponsor without deduction to amounts owed to Covance. 

 

	6.	 SITE VISITS 

  

	 	6.1	 The Sponsor or its representative (which shall not be a competitor of Covance) may visit Covance’s
premises where the Services are being performed at reasonable times, on reasonable notice and with reasonable frequency during normal business hours to observe the progress of the Services. Covance will assist the Sponsor in scheduling such visits.

  

	 	6.2	 The Sponsor acknowledges that the Sponsor’s representatives granted access to Covance facilities
during any such visits may have access to confidential and proprietary information of Covance. The Sponsor agrees that all such confidential and proprietary information of Covance obtained or observed by the Sponsor during such visits shall remain
the sole property of Covance and the Sponsor shall treat such information as Confidential Information in accordance with Section 8 of this Agreement 

  
 8 of 21 

	7.	 REGULATORY INSPECTIONS AND AUDITS 

 

	 	7.1	 In the event of a Party receiving a notice from a Regulatory Authority which directly relates to the
Services, the Party receiving such notice shall promptly notify the other Party or forward to the other Party a copy of such notice (or extract thereof). Each Party will cooperate with the other in responding to such notice before referring to the
other Party in any regulatory correspondence or disclosing any Confidential Information to a Regulatory Authority. However, each Party acknowledges that it may not direct the manner in which the other Party fulfils its obligations to permit
inspection by Regulatory Authorities. 

  

	 	7.2	 Covance shall cooperate with any inspection or audit by a Regulatory Authority and shall notify the
Sponsor promptly of any request by a Regulatory Authority. 

  

	 	7.3	 Covance agrees that, during an inspection or audit by a Regulatory Authority concerning the Services, it
will not disclose information and materials that are not required to be disclosed to such Regulatory Authority, without the prior written consent of the Sponsor. 

 

	 	7.4	 If any inspections or audits conducted pursuant to this Section 7 that result in a finding that
Covance has failed to comply with the terms of this Agreement, Covance shall promptly take such measures at its own cost and expense as are necessary to correct such defaults. 

 

	 	7.5	 It is agreed that where any audit of Covance concerns or relates to referral laboratory testing or
shipping methods of Covance, the Sponsor or its representative (which shall not be a competitor of Covance) may only confirm or not if Covance is properly billing such costs. The Sponsor expressly agrees that Sponsor’s representatives may not
directly or indirectly provide any details of the charges to the Sponsor, such as the actual amount of the referral laboratory testing or shipping costs incurred by Covance. 

 

	8.	 CONFIDENTIAL INFORMATION 

 

	 	8.1	 Each Party agrees that all Confidential Information of the Disclosing Party is and shall be the sole
property of the Disclosing Party. 

  

	 	8.2	 Without prejudice to any Covance Property, all Results, information, data and records developed by
Covance or its Affiliates in the performance of the Services shall be the Confidential Information of the Sponsor. 

  

	 	8.3	 Each Party agrees to hold the Confidential Information of the other Party in confidence and in a manner
consistent with the way in which it maintains the confidentiality of its own proprietary information, being at least a reasonable standard of care. Each Party shall disclose the Confidential Information only on a need to know basis, to its
employees, officers, directors, representatives and third party investigators, in each case who are legally bound to treat the Confidential Information in the manner set forth in this Section 8. 

  
 9 of 21 

	 	8.4	 Recipient agrees that, except as necessary to fulfil its obligations under this Agreement, it will not
use any of the Confidential Information of the Disclosing Party. 

  

	 	8.5	 Notwithstanding the non-disclosure obligations herein, Recipient
shall not be in breach of this Section 8 if it discloses Confidential Information to the extent such disclosure is required by Applicable Law or a court or administrative subpoena or order; provided, however, that (a) any such disclosure
shall not otherwise relieve Recipient of its continuing confidentiality and non-use obligations hereunder with respect to all of the Confidential Information, including the information disclosed by it to the
court or agency under this Section 8 and (b) Recipient shall give Disclosing Party reasonable advance notice of any such disclosure and cooperate reasonably with Disclosing Party (and at Disclosing Party’s expense) in Disclosing
Party’s efforts to object to such disclosure and to obtain the court’s or administrative agency’s agreement to maintain the confidentiality of the Confidential Information to be disclosed by Recipient under this Section 8.

  

	 	8.6	 The obligations in this Section 8 shall remain in full force and effect for a period of seven
(7) years following termination of this Agreement except with respect to Confidential Information which is considered a trade secret under Applicable Law, which shall remain confidential as long as such Confidential
Information retains its status as a trade secret. 

  

	 	8.7	 Misuse or disclosure of the Confidential Information by Recipient may cause irreparable harm to
Disclosing Party not adequately compensable by money damages. In the event of actual or threatened breach or violation of this Section 8, the disclosing Party shall have the right to seek injunctive relief in any court of competent
jurisdiction, without the need to post any bond and without the need to demonstrate actual damages. 

  

	9.	 INTELLECTUAL PROPERTY RIGHTS 

 

	 	9.1	 All Background IP is and shall remain the exclusive property of the Party owning it and except as
expressly provided in this Agreement, no Party shall acquire any rights in or to the Background IP of the other Party. 

  

	 	9.2	 The Sponsor acknowledges that Covance Property is owned or licensed by Covance or its Affiliates.
Strategic insight and proposed Project design and scope provided in any quotation by Covance shall remain the property of Covance and may be used by the Sponsor only to assess whether it wishes to pursue such work with Covance.

  

	 	9.3	 The Sponsor will have title to the Deliverables and all intellectual property rights therein. Subject to
RMCL’s payment of amounts due to Covance hereunder, Covance assigns all rights in and to the Deliverables to the Sponsor, except that one (1) copy of the Results may be retained by Covance solely for regulatory or legal compliance
purposes. The Sponsor hereby grants Covance an unrestricted, royalty-free license to aggregate and use System Data produced by or for Covance as part of the Services with other System Data owned or licensed by Covance only if Sponsor is not
identifiable through Covance’s aggregation and use. 

  
 10 of 21 

	 	9.4	 Covance shall promptly disclose to the Sponsor (or its nominee) all Inventions. Covance assigns and
agrees to assign to the Sponsor (or its nominee) all rights, title and interest in and to such Invention and shall do all acts that are reasonably necessary to vest the Invention in the name of the Sponsor (or its nominee), at Sponsor’s
expense. 

  

	10.	 REMEDIES AND LIMITATION OF LIABILITY 

 

	 	10.1	 In the event of a material error by Covance that prevents proper performance under this Agreement or
which renders the Services in whole or in part unacceptable to a Regulatory Authority to which the Sponsor intends to submit the Results, Covance’s sole obligation to Sponsor (other than the obligations set forth in Section 11) shall be
for Covance, at Sponsor’s election, to either: (a) repeat the defective part of the Services at Covance’s own cost; or (b) refund to the Sponsor the amount paid for the defective part of the Services. 

 

	 	10.2	 Except for liability resulting from any breach of Sections 8 or 9 or liability pursuant to
Section 11, Covance’s total liability to the Sponsor, whether in contract, tort (including negligence) or otherwise, shall in no circumstances exceed the total price paid by the Sponsor for the Services that are the subject of this
Agreement. 

  

	 	10.3	 Nothing in this Agreement excludes or limits the liability of either Party where liability cannot be
excluded or restricted as a matter of law. 

  

	 	10.4	 Except for liability resulting from any breach of Sections 8 or 9 or liability pursuant to
Section 11, Covance will not be liable to the Sponsor for any Loss in respect of any: 

  

	 	(a)	 loss of profit, opportunity, business, or goodwill (in each case whether direct or indirect); or

  

	 	(b)	 any indirect, consequential, punitive, exemplary or special damages or losses, arising under or in connection
with this Agreement, 

  

	 	(c)	 and each type of loss arising under this Section 10.4 shall be severable in accordance with
Section 22 of this Agreement. To the extent that Covance agrees to perform Services for Sponsor Affiliates, Covance shall only be liable to the entity named in this Agreement and not for multiple claims by Sponsor Affiliates.

  

	 	10.5	 Covance shall not be liable for any failure, error or delay in performing the Services if such failure,
error or delay is directly caused by Sponsor, but Covance will cooperate with Sponsor to minimize any such delay and to correct any such failure or error. 

  

	 	10.6	 Covance shall have no liability to Sponsor for loss, damage, delay or non-delivery/non-collection of any samples or shipment dispatched by Covance to Sponsor or to any third party designated by Sponsor in connection with the Services that are caused by the acts or omissions of
any third party delivery services or carrier (“Carrier”). Notwithstanding the foregoing, to the extent permitted by law, Covance shall have the benefit of any right or remedy permitted under international or domestic law and any
sums recoverable from a Carrier shall be paid to the Sponsor. For the avoidance of doubt, a Carrier is not considered a Subcontractor for the purposes of this Agreement. 

  
 11 of 21 

	11.	 INDEMNITIES 

  

	 	11.1	 The Sponsor shall defend, indemnify, and hold harmless Covance and its respective Affiliates and their
respective officers, directors, employees and agents (Covance Group) from any Loss resulting from any Claim arising from or related to: 

  

	 	(a)	 personal injury to a participant in the Study directly or indirectly caused by the Test Material;

  

	 	(b)	 Covance’s proper execution and/or the proper performance of its obligations under this Agreement;

  

	 	(c)	 the Sponsor’s use of the Results or Deliverables or its use or marketing of any substance tested in
association with the Study by Covance; 

  

	 	(d)	 the negligence or intentional misconduct of the Sponsor; 

 

	 	(e)	 the Test Material’s harmful or otherwise unsafe effect, including, without limitation, a product liability
claim based upon the Sponsor’s or Sponsor’s representatives’ use, consumption, sale, distribution or marketing of the Sponsor’s products tested under this Agreement; or 

 

	 	(f)	 the infringement, unlawful disclosure or misappropriation of copyright, patent, trade secret or other
intellectual property of a third party by reason of Covance’s use of the Sponsor Information in accordance with the terms of this Agreement, 

provided that if such Loss or Claim arises in whole or in part from Covance’s negligence or intentional misconduct, then the amount of
such Loss that Sponsor shall indemnify the appropriate person or entity within the Covance Group pursuant to this Section 11 shall be reduced by an amount in proportion to the percentage of Covance’s responsibilities for such Loss as
determined by a court of competent jurisdiction in a final and non-appealable decision or in a binding settlement between the Parties. 
  

	 	11.2	 Covance shall defend, indemnify and hold harmless the Sponsor and its Affiliates and their respective
officers, directors and employees (the “Sponsor Group”) from any Loss resulting from any Claim arising from a breach of this Agreement by Covance, or the negligence or intentional misconduct of Covance, provided that if such
Losses or Claims arise in whole, or in part, from the Sponsors Group’s negligence or intentional misconduct, then the amount of such Losses that Covance shall be responsible for pursuant to this Section 11 shall be reduced by an amount in
proportion to the percentage of the Sponsor Group’s responsibilities for such Losses as determined by a court of competent jurisdiction in a final and non-appealable decision or in a binding settlement
between the Parties. 

  
 12 of 21 

	 	11.3	 An indemnitee entitled to indemnification under Section 11 (the “Indemnified
Party”) shall give written notice to the other Party (“Indemnifying Party”) of a claim or other circumstances likely to give rise to a request for indemnification, promptly after the Indemnified Party becomes aware of the
same. The Indemnifying Party shall be afforded the opportunity to undertake the defense of, and, subject to Section 11.5, to settle by compromise, or otherwise, any claim for which indemnification is available under this Section.

  

	 	11.4	 If the Indemnifying Party assumes the defense of any claim, the Indemnified Party may participate in
such defense with legal counsel of its selection and at its expense. If the Indemnifying Party fails to promptly assume the defense of a claim by the Indemnified Party under this Section 11.4, the Indemnified Party may thereupon undertake the
defense on behalf of, at the risk and expense of the Indemnifying Party with all reasonable costs and expenses of such defense to be paid by the Indemnifying Party. 

 

	 	11.5	 In the event that the Indemnifying Party assumes the defense of any claim, no compromise or settlement
of any such claim may be made without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. 

  

	12.	 INSURANCE 

  

	 	12.1	 Covance shall secure and maintain in full force and effect through the performance of the Services the
necessary insurance coverage in amounts appropriate to the conduct of Covance’s business. Certificates evidencing such insurance will be made available for examination upon written request by Sponsor. 

 

	 	12.2	 Sponsor hereby warrants and represents that it maintains and shall maintain adequate clinical trial and
product liability insurance coverage consistent with industry standards and in compliance with all Applicable Laws. Certificates evidencing such insurance will be made available for examination upon written request by either Covance or Sponsor.

  

	13.	 HUMAN BIOLOGICAL SAMPLES 

 

	 	13.1	 Where the Sponsor supplies HBS to Covance, the Sponsor represents and warrants that:

  

	 	(a)	 all HBS supplied under this Agreement are or have been procured and reviewed by ethics committee and supplied
to Covance in full compliance with any and all Applicable Laws and Regulatory Requirements relating to the Use of HBS providing protection for human subjects in the country of origin; 

 

	 	(b)	 the HBS Donor has given Informed Consent; and 

 

	 	(c)	 all HBS supplied to Covance: (i) may be Used for the Services; (ii) may be used to provide data in
support of commercial product development; and (iii) were procured without inappropriate financial benefit to the HBS Donor. 

  
 13 of 21 

	 	13.2	 The Sponsor shall: (a) upon request, provide a copy of the relevant Informed Consent template; and
(b) ensure any HBS shall be de-identified or ‘coded’ according to applicable Regulatory Requirements to protect the identity and confidentiality of the HBS Donor. Full date of birth shall only
be collected if medically relevant to the Services (unless legally restricted in the country of operation). In the event of a withdrawal of, or a material variation to the Informed Consent (including any material changes that may affect the Services
provided by Covance) the Sponsor shall promptly notify all relevant Covance entities of such changes. 

  

	 	13.3	 Covance agrees to Use the HBS in accordance with all applicable Regulatory Requirements.

  

	 	13.4	 Upon Sponsor’s request, Covance shall retain, return or destroy all HBS in accordance with the
Informed Consent, the Sponsor’s instructions or any other specific requirements under Applicable Law and Regulatory Requirements. 

  

	 	13.5	 The Sponsor acknowledges that where Covance enters into a material transfer agreement
(“MTA”) with the provider of any HBS, Covance shall act in accordance with the terms of the MTA and the disposition of the relevant HBS shall be as prescribed in the MTA. In the event of a conflict between the terms of the MTA, this
Agreement, any Work Order and any instructions provided by the Sponsor, the terms of the MTA shall prevail. 

  

	14.	 DATA PROTECTION 

 

	 	14.1	 Where Covance processes any personal data on behalf of the Sponsor, Covance shall process such personal
data in accordance with all applicable Data Protection Laws in the territories in which the Services are performed (“Protected Data”). 

  

	 	14.2	 If Covance processes any Protected Data on behalf of the Sponsor, Covance and the Sponsor each agree and
acknowledge that the Sponsor shall be the data controller and Covance shall be the data processor with respect to the processing of such Protected Data. Covance shall only process such Protected Data on behalf and upon the reasonable instructions of
the Sponsor for purposes notified to it by the Sponsor for which consent from the relevant data subjects has been obtained in accordance with all applicable Regulatory Requirements. Covance shall follow such procedures, policies and reasonable
instructions as may be agreed by the Parties from time to time. 

  

	 	14.3	 Covance shall take reasonable technical and organizational measures that are necessary to protect
against the unauthorized or unlawful processing of or the unauthorized or unlawful disclosure of such personal data. Covance shall promptly notify the Sponsor in the event of a security breach involving any personal data which Covance is processing
on behalf of the Sponsor. 

  

	 	14.4	 The Sponsor warrants that it has complied with any and all notification and information requirements
under the applicable Data Protection Laws. 

  
 14 of 21 

	15.	 SUBCONTRACTORS 

 

	 	15.1	 Notwithstanding Section 18, certain tasks, as may be agreed during the development of and specified
in the Protocol, may be subcontracted by Covance to Subcontractors approved by Covance or subcontracted, or assigned and transferred to its Affiliates. Covance shall be responsible for the acts and performance of Subcontractors and Affiliates.

  

	 	15.2	 Covance shall not be responsible for the performance of third party Vendors. Liability of Covance to the
Sponsor with respect to such Vendors shall be limited to the extent Covance is negligent in the performance of its obligations under this Agreement. Covance shall provide to the Sponsor any amounts that Covance may recover from such Vendors as a
result of any error or service failure on the part of the Vendors in connection with this Agreement. 

  

	16.	 FORCE MAJEURE 

 

	 	16.1	 Neither Party shall be in breach of this Agreement nor liable for delay in performing, or failure to
perform, any of its obligations under this Agreement, if such delay or failure result from a Force Majeure Event. In such circumstances, any time specified for completion of performance in the Protocol falling due during or subsequent to the
occurrence of a Force Majeure Event shall be automatically extended for a period of time equal to such event. 

  

	 	16.2	 Should any part of the Services be rendered invalid as a result of a Force Majeure Event, Covance shall,
upon written request from the Sponsor, and at the Sponsor’s sole cost and expense, repeat the affected part of the Services. 

  

	 	16.3	 If a Force Majeure Event prevents a Party from performing pursuant to this Agreement for a period of 180
days or more, the unaffected Party may terminate this Agreement upon written notice to the affected Party. 

  

	17.	 INDEPENDENT CONTRACTOR 

 

	 	17.1	 The Parties agree that in performing the Services, Covance (including its employees, agents,
subcontractors or other representatives) is acting as an independent contractor to Sponsor. The Parties further agree that Covance and its employees, agents, subcontractors or other representatives are not employees, agents or partners of Sponsor,
and nothing in this Agreement and no actions of Sponsor in engaging Covance shall render Covance or any of its employees, agents, subcontractors or other representatives the employees, agents or partners of Sponsor. Neither Covance nor any of its
employees, agents, subcontractors or other representatives will have power or authority to bind Sponsor. Neither the relationship between Covance and Sponsor nor any provision of this Agreement shall be construed to authorize Covance to take (or
fail to take) any action or make (or fail to make) any decision, representation or commitment binding upon Sponsor or any of its affiliate companies. Sponsor shall at all times be free to engage other third parties to perform services in addition to
or in lieu of those services being provided by the Covance. Subject to the provisions of this Agreement, Covance shall be free to devote such time that they do not spend providing Services under this Agreement to such person, firms or corporations
as they may choose. 

  
 15 of 21 

	 	17.2	 Nothing contained herein shall be construed (i) to create any association, partnership, joint
venture, or relationship of principal and agent, or master and servant between the Parties or any of their affiliates or subsidiaries, employees and subcontractors, (ii) to provide any Party with the right, power or authority, either express or
implied, to create any duty or obligation on behalf of another Party, (iii) to impose liability upon one Party for the act or failure to act of another Party, or (iv) to confer any right for Covance (or any of its employees, agents,
subcontractors or other representatives) to participate in or be eligible to participate in any pension or welfare benefit plans, programs or arrangements of Sponsor or of its affiliate companies pertaining to any pension, stock, bonus, profit
sharing or similar benefits or any employee health, life assurance, workers compensation insurance, disability, severance or any other benefit of any kind whatsoever which is associated with or customarily paid in connection with or in relation to
an employment contractor. 

  

	18.	 ASSIGNMENT 

  

	 	18.1	 Either Party may assign, transfer or subcontract any or all of its rights and obligations under this
Agreement to its Affiliates. 

  

	 	18.2	 Notwithstanding Section 18.1 and except in connection with an internal reorganization of the
relevant Party’s corporate structure, this Agreement shall not be assigned or transferred in whole or in part by either Party without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed.

  

	19.	 NOTICES 

  

	 	19.1	 All notices required to be given under this Agreement shall be in writing and shall be deemed to have
been duly given if delivered personally or mailed first class, registered or certified mail, return receipt requested, postage paid: 

If to Sponsor to: 
 RegenMed
(Cayman) Ltd. 
 10 Market St. 

#774 Camana Bay, Grand Cayman 

KY 1-90006 Cayman Islands 

    Attention: ________________________ 

With a copy by email to: 
 If to
Covance to: 
 Covance Central Laboratory Services LP 

8211 SciCor Drive 

Indianapolis, Indiana 46214-2985 

UNITED STATES 
 Attention: VP,
Finance 

  
 16 of 21 

 or at such other place as either Party shall hereafter furnish to the other Party in
writing. Notices shall be deemed given on the date of personal delivery or deposit in the mail as specified above. 
  

	 	19.2	 For the purposes of this Section 19, in relation to the purposes of any legal proceeding,
“writing” shall not include email. 

  

	20.	 WAIVER 

No waiver of any term, provision, or condition of this Agreement whether by conduct or otherwise in any one or more instances shall be deemed
to be or construed as a further or continuing waiver or estoppel of any such term, provision, or condition or of any other term, provision, or condition of this Agreement. 
  

	21.	 VARIATION 

No provision of this Agreement may be amended, modified, varied, discharged, or terminated except by the express written agreement of both
Parties and signed by an authorized representative of each Party. 
  

	22.	 SEVERABILITY 

If any court or competent authority finds that any provision of this Agreement (or part of any provision) is invalid, illegal or unenforceable,
that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this Agreement shall not be affected. If any invalid, unenforceable or illegal provision of this
Agreement would be valid, enforceable and legal if some part of it were deleted, the provision shall apply with the minimum modification necessary to make it legal, valid and enforceable. 

 

	23.	 PUBLICITY AND PUBLICATION 

 

	 	23.1	 Neither Party will use the name, trademark or the name of any representative of the other, or the
existence of this Agreement for any promotional or advertising purposes, or any other publication, without the prior written consent of the other. 

  

	 	23.2	 Neither Party will state or imply that the other Party endorses or approves any service, material,
product or compound of the other Party without the prior written consent of the other. Such restrictions shall not apply to internal communications and publications to a Party’s Affiliates. 

 

	 	23.3	 Sponsor shall provide Covance with a pre-publication copy of any
report, manuscript, publication or form of marketing material recognizing Covance’s participation in the Services or otherwise identifying Covance, for approval (which approval shall not be unreasonably withheld or delayed) in each case at
least thirty (30) days before its submission for publication. 

  
 17 of 21 

	24.	 ENTIRE AGREEMENT 

This Agreement represents the entire understanding between the Parties with respect to the subject matter hereof as of the Effective Date, and
this Agreement supersedes all prior agreements, negotiations, understandings, representations, statements and writings between the Parties relating thereto, except that any written agreement entered into prior to the Effective Date with respect to a
Study in process prior to the Effective Date shall remain effective and shall continue to govern such existing Study. The Parties agree that neither has relied upon prior representations made before executing this Agreement. 

 

	25.	 LEGAL TESTIMONY 

Covance agrees to provide testimony or records regarding the Services for the Sponsor in any legal or administrative proceeding, provided that
the Sponsor shall reimburse Covance for its out of pocket costs plus a reasonable hourly fee for the involvement of its employees or representatives in such proceedings. 
  

	26.	 THIRD PARTY RIGHTS 

Except as expressly set forth in this Agreement in respect of Covance Affiliates, nothing in this Agreement is intended to confer any rights,
benefits or remedies of any kind whatsoever, and a person who is not a party to this Agreement shall have no right to enforce any of its terms. 
  

	27.	 ANTI-BRIBERY 

  

	 	27.1	 Both Parties agree that each has not and will not, either directly or indirectly, engage in bribery, or
offer, or promise, or authorize to pay or make any improper payment of any monies or financial or other advantage, including cash, loan, gift, travel, entertainment, hospitality, facilitation payment, kickback, political or philanthropic
contribution, anything of value, or any other perceived benefit to improperly obtain or retain a business advantage in violation of any Anti-Corruption Laws and further, each Party agrees that they shall not take any action that would cause the
other Party to be in violation of such Anti-Corruption Laws. 

  

	 	27.2	 Any breach of Section 27.1 by a Party shall allow the other Party to immediately terminate this
Agreement. 

  

	28.	 TRADE CONTROL 

 

	 	28.1	 Notwithstanding any other provision of this Agreement to the contrary, each Party shall comply with, and
retain responsibility for its compliance with, all applicable export control laws (e.g., the U.S. Export Administration Regulations) and economic sanctions programs (e.g., economic sanctions maintained by the U.S. Treasury Department, as well as
Specially Designated Nationals and Blocked Persons (SDNs)) relating to its respective business, facilities, and the provision of services to third parties (collectively, Trade Control Laws). 

  
 18 of 21 

	 	28.2	 Nothing in this Agreement shall be construed to require Covance to be directly or indirectly involved in
the provision of goods, software, services and/or technical data that may be prohibited by applicable Trade Control Laws, including sanctions currently in place against Cuba, Iran, North Korea, Sudan, Syria and SDNs. 

 

	29.	 COUNTERPARTS 

This Agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original to this
Agreement but all of which together shall constitute the same Agreement. Signatures upon this Agreement transmitted by facsimile, electronic mail or other electronic method shall have the same legal and biding effect as wet signatures. 

 

	30.	 CHOICE OF LAW AND DISPUTE RESOLUTION 

 

	 	30.1	 This Agreement shall be governed and construed in accordance with the laws of the State of New York,
U.S.A., without regard to conflicts of laws provisions. 

  

	 	30.2	 Any dispute, controversy, or claim arising out of, relating to, or in connection with this Agreement, or
the breach, termination, or validity thereof, shall be finally settled by arbitration. The arbitration shall be conducted in accordance with the Securities Arbitration Rules (the “Rules”) of the American Arbitration Association
(“AAA”), including the AAA’s Procedures for Large, Complex Commercial Disputes, in effect at the time of the arbitration, except as they may be modified herein or by mutual agreement of the parties. The seat of the arbitration shall
be New York, New York, and it shall be conducted in the English language. The arbitration and this clause shall be governed by Title 9 (Arbitration) of the United States Code. The Parties agree that irreparable damage may occur to a Party in the
event that the other Party may fail or fails to comply with the provisions of Section 8. Accordingly and without otherwise limiting the requirement of mandatory arbitration imposed hereunder, a Party may seek from any court having jurisdiction
any interim or provisional relief (without the necessity of posting bond) that may be necessary to protect its interests under Section 8, pending the arbitral tribunal’s final determination of the merits of the controversy.

  

	 	30.3	 The arbitration shall be conducted by three arbitrators. The claimant shall appoint an arbitrator in its
request for arbitration. The respondent shall appoint an arbitrator within twenty (20) days of the receipt of the request for arbitration. The two arbitrators shall appoint a third arbitrator, who shall act as chair of the tribunal, within
twenty (20) days after the appointment of the second arbitrator. If any of the three arbitrators is not appointed within the time prescribed above, then the AAA shall appoint that arbitrator from its National Panel of Securities Arbitrators or
its Large, Complex Commercial Case Panel, not including any such members affiliated with the securities industry. The chair of the tribunal shall be a citizen of the United States. 

  
 19 of 21 

	 	30.4	 In addition to the authority conferred on the arbitration tribunal by the Rules, the arbitration
tribunal shall have the authority to order such production of documents, generally consistent with the discovery permitted under the Federal Rules of Civil Procedure, as may reasonably be requested by any party or by the tribunal itself. In
addition, any party may request a reasonable number of depositions of party witnesses. 

  

	 	30.5	 The Parties agree that the arbitration shall be kept confidential and that the existence of the
proceeding and any element of it (including but not limited to any pleadings, briefs or other documents submitted or exchanged, any testimony or other oral submissions, and any awards) shall not be disclosed beyond the tribunal, the AAA, the
Parties, their counsel, accountants and auditors, insurers and re-insurers, and any person or entity necessary to the conduct of the proceeding. The confidentiality obligations in this Section 28.5 shall
not apply (i) if disclosure is required by Applicable Law, or in judicial or administrative proceedings, or (ii) as far as disclosure is necessary to enforce the rights arising out of the award. 

 

	 	30.6	 The arbitration award shall be final and binding on the Parties. Judgment upon the award may be entered
by any court having jurisdiction thereof or having jurisdiction over the relevant Party or its assets. 

  

	 	30.7	 In order to facilitate the comprehensive resolution of related disputes, and upon request of any party
to the arbitration proceeding, the arbitration tribunal may consolidate the arbitration proceeding with any other arbitration proceeding involving any of the Parties hereto relating to this Agreement. The arbitration tribunal shall not consolidate
such arbitrations unless it determines that (i) there are issues of fact or law common to the related proceedings so that a consolidated proceeding would be more efficient than separate proceedings, and (ii) no party would be prejudiced as
a result of such consolidation through undue delay or otherwise. 

  

	 	30.8	 The Parties agree that any dispute arising from or in connection with this Agreement (including any non-contractual obligations) shall be referred to and finally resolved by arbitration under the Rules of the International Chamber of Commerce which Rules shall be deemed incorporated by reference to the Agreement.
The number of arbitrators shall be three (3), the seat or legal place of arbitration shall be New York and the language used in the arbitration shall be English. 

[signature page follows] 

  
 20 of 21 

 IN WITNESS WHEREOF, the Parties by their duly authorized officers have executed this Agreement on the dates
set forth below, to be effective on the Effective Date set forth on the first page of this Agreement. 
  

			
	RegenMed (Cayman) Ltd.
		
	Signature:	 	/s/ Alasdair Foster
	Name:	 	Alasdair Foster
	Title:	 	Director
	Date:	 	29 August 2016

  

			
	COVANCE CENTRAL LABORATORY SERVICES LP
	COVANCE CENTRAL LABORATORY SERVICES SÀRL
		
	Signature:	 	/s/ Cheryl Helton
	Name:	 	Cheryl Helton
	Title:	 	VP, Covance CLS
	Date:	 	8/29/2016

  
 21 of 21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]